Ranbaxy ''disappointed'' over USFDA move

New Delhi, Sep 17 (UNI) Ranbaxy Laboratories, country's top drug maker by sales, today said it is disappointed by the US Food and Drug Administration's (USFDA) move to ban dozens of its generics.

''The company has responded to each concern the USFDA has raised during the past two years and had thought that progress was being made,'' a company statement said.

The USFDA had yesterday said it would block more than 30 generic drugs from entering the US following ongoing procedural violations in manufacturing at Ranbaxy's Dewas and Paonta Sahib plants.

UNI SR RN121220